Surabgene Lomparvovec
AssetAlso ABBV-RGX-314, Sura-vec
Delivers a gene encoding an anti-VEGF antibody fragment to suppress abnormal retinal blood vessel growth and leakage.
- Stage
- Phase 3
- Modality
- Gene therapy
- Target
- VEGFA
- 3
- Indications
- 2
- Trials
- 2
- Developers
Indications
3Neovascular age-related macular degeneration
Phase 3, Recruiting, NCT07007065, clinicaltrials.gov, 10 Oct 2026
Wet age-related macular degeneration
Phase 3, prnewswire.com, 12 Oct 2026
Diabetic retinopathy
Phase 2, Recruiting, NCT07592273, clinicaltrials.gov, 10 Oct 2026
In the full profile
- Targets and what it contains1
- Owner and partners2
- Trials2
- Evidence for its targets1
- Competitors11
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.